id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-342254-vdovpfu1	Mugheddu, C.	CID‐19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management	2020-06-04		.txt	text/plain	766	54	45	title: CID‐19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management Novel coronavirus 2019 (SARS-CoV2) pandemic has particularly affected Italy, with a profound impact on the therapeutic strategy for complex disorder such as psoriasis, whose extensive skin damage might expose to an increased infective risk compared to the general population. Psoriasis treatment relies on immunosuppression, and although most experts agree that the benefit-to risk-ratio is in favor of maintaining selective biologic therapies, and small molecules such as apremilast, they recommend dismission if severe COVID-19 symptoms occur. The fact that patient with a severe form of psoriasis contracted the COVID-19 pneumonia, while on treatment with apremilast is worth of some considerations. 11 Recently, another Italian psoriasis patient contracting COVID-19 under IL-23 inhibitor treatment (guselkumab) has been reported, and completely recovered from the infection. 12 From our experience, apremilast confirms its safety in very critical patients with severe infections, including COVID-19.	./cache/cord-342254-vdovpfu1.txt	./txt/cord-342254-vdovpfu1.txt